SCHEMBL31437491

SCHEMBL31437491

Cn1cc(NC(=O)OC(C)(C)C)c(Br)n1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.40
▸ BRD9 Q9H8M2 1/20 0.39
▸ IRAK4 Q9NWZ3 4/20 0.39
▸ GSK3B P49841 1/20 0.39
▸ DYRK1A Q13627 1/20 0.39
▸ CNR2 P34972 1/20 0.37
▸ ATR Q13535 1/20 0.37
▸ CA1 P00915 1/20 0.37
▸ CA2 P00918 1/20 0.37
▸ PTGDR2 Q9Y5Y4 1/20 0.36
▸ MAPK14 Q16539 1/20 0.36
▸ METAP1 P53582 1/20 0.36
▸ ATM Q13315 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ LCK P06239 1/20 0.35
▸ ADORA3 P0DMS8 1/20 0.35
▸ ADORA2A P29274 1/20 0.35
▸ ADORA1 P30542 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20276702 0.86 LMNA (0.47) LMNABRD9IRAK4GSK3BDYRK1A
SCHEMBL20262443 0.82 IRAK4 (0.41) LMNABRD9IRAK4GSK3BDYRK1A
SCHEMBL22857998 0.81 IRAK4 (0.45) LMNABRD9IRAK4GSK3BDYRK1A
SCHEMBL27457955 0.79 ATR (0.39) LMNABRD9IRAK4GSK3BDYRK1A
SCHEMBL22857997 0.79 CNR2 (0.53) BRD9IRAK4GSK3BDYRK1ACNR2
SCHEMBL27457954 0.79 GSK3B (0.40) LMNABRD9IRAK4GSK3BDYRK1A
SCHEMBL15885557 0.79 NPSR1 (0.54) LMNABRD9GSK3BDYRK1ACA1
SCHEMBL31555029 0.78 IRAK4 (0.41) IRAK4
SCHEMBL31439890 0.78 GSK3B (0.39) LMNABRD9IRAK4GSK3BDYRK1A
SCHEMBL18138349 0.77 L3MBTL1 (0.39) LMNABRD9IRAK4GSK3BDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125389-A1 MEMBRANE-ASSOCIATED TYROSINE AND THREONINE KINASE INHIBITOR AND USE THEREOF HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO LTD (CN) 2026-05-07 — — US disclosed
CN-119894902-A Membrane associated tyrosine and threonine kinase inhibitors and uses thereof 海南先声再明医药股份有限公司 2025-04-25 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125389-A1 MEMBRANE-ASSOCIATED TYROSINE AND THREONINE KINASE INHIBITOR AND USE THEREOF PKMYT1, PKN1, ROS1 LMNA 1486/4885BRD9 3770/4885IRAK4 1305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback